In 2022,Zhou, Zongtao; Cai, Zongyu; Zhang, Congzi; Yang, Benhui; Chen, Lianru; He, Yepu; Zhang, Luyong; Li, Zheng published an article in Bioorganic & Medicinal Chemistry. The title of the article was 《Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold》.Product Details of 2398-37-0 The author mentioned the following in the article:
The free fatty acid receptor 1 (FFA1/GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have been widely considered as promising targets for type 2 diabetes mellitus (T2DM) due to their resp. roles in promoting insulin secretion and improving insulin sensitivity. Hence, the dual FFA1/PPARδ agonists may exert synergistic effects by simultaneously activating FFA1 and PPARδ. The present study performed systematic exploration around previously reported FFA1 agonist compound I (lead compound), leading to the identification of a novel dual FFA1/PPARδ agonist compound II (the optimal compound), which displayed high selectivity over PPARα and PPARγ. In addition, the docking study provided detailed binding modes of the optimal compound II in FFA1 and PPARδ. Furthermore, the optimal compound II exhibited greater glucose-lowering effects than lead compound I, which might attribute to its synergistic effects by simultaneously modulating insulin secretion and resistance. Moreover, the optimal compound II has an acceptable safety profile in the acute toxicity study at a high dose of 500 mg/kg therefore, the results provided a novel dual FFA1/PPARδ agonist with excellent glucose-lowering effects in vivo. After reading the article, we found that the author used 1-Bromo-3-methoxybenzene(cas: 2398-37-0Product Details of 2398-37-0)
1-Bromo-3-methoxybenzene(cas: 2398-37-0) can be used in chemical reaction as intermediates to obtain target materials such as dyes, pharmaceuticals, perfumes, photoinitiators and agrochemicals.Product Details of 2398-37-0
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem